AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
30 Winter Street
Boston
Massachusetts
02108
United States
451 articles with AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
-
AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference
9/21/2022
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will participate in a panel discussion at the Cantor Fitzgerald Oncology & HemOnc Conference.
-
AVEO Oncology Announces Participation at Investor Conferences in September
8/31/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are scheduled to participate in three investor conferences in September.
-
AVEO Oncology Reports Second Quarter 2022 Financial Results
8/4/2022
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reported financial results for the second quarter ended June 30, 2022.
-
AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022
7/28/2022
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022.
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
6/22/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement in North America with Eli Lilly and Company (Lilly) to evaluate ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
-
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
6/21/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022.
-
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
6/6/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology focused biopharmaceutical company, presented three posters during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting highlighting data for tivozanib, the Company’s oral, once-daily next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) designed to block the VEGF pathway by potently and selectively inhibiting all three VEGF receptors.
-
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
5/18/2022
AVEO Oncology announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. eastern time.
-
AVEO Oncology Reports First Quarter 2022 Financial Results
5/5/2022
AVEO Oncology today reported financial results for the first quarter ended March 31, 2022.
-
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
4/28/2022
AVEO Oncology today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022.
-
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
3/14/2022
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, reported financial results for the fourth quarter and full year ended December 31, 2021, and provided financial guidance for 2022.
-
AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022
3/7/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022.
-
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
2/14/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that new long-term progression free survival (PFS) data from the Phase 3 TIVO-3 study, which compares FOTIVDA® (tivozanib) to Nexavar® (sorafenib) in advanced renal cell carcinoma (RCC) patients following two or more prior systemic therapies, are being presented at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.
-
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
1/20/2022
AVEO Oncology announced that new efficacy and safety data from the first line of the phase 1b/2 DEDUCTIVE study of FOTIVDA® in combination with IMFINZI® in previously untreated metastatic hepatocellular carcinoma are being presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
AVEO Oncology Highlights Recent Progress and 2022 Outlook
1/4/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022.
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC
1/4/2022
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to evaluate ficlatuzumab in combination with ERBITUX ® (cetuximab), an EGFR-targeted antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ficlatuzumab is AVEO’s investigational potent
-
AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference
12/22/2021
AVEO Oncology today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th.
-
BioSpace Movers & Shakers, Dec. 3
12/3/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.